Dry Eye Therapy Utilizing Cationic Novasorb® Technology Available Soon From OCuSOFT®

RICHMOND, Texas, June 14, 2011 /PRNewswire/ -- OCuSOFT, Inc., an ophthalmic pharmaceutical research, development and supply company today announced an exclusive multiyear agreement with Ardeo Health, LLC to distribute a novel dry eye therapy under license from Novagali Pharma S.A. of Evry, France, Nova23041.

Nova23041 will be marketed and distributed in the United States and Canada as Retaine® MGD™ Ophthalmic Emulsion under a brand license from OCuSOFT, Inc. Utilizing Novagali's Novasorb® Technology—a proprietary cationic process of binding positively charged ions to the negatively charged ocular surface, Retaine® MGD™ will prolong corneal contact time resulting in enhanced comfort. As a preservative-free oil-in-water emulsion, Retaine® MGD™ will target individuals suffering from Meibomian Gland Dysfunction, a component of Dry Eye Syndrome.

Cynthia Barratt, President and CEO of OCuSOFT, Inc. comments, "OCuSOFT® has been searching for a truly unique proprietary Dry Eye therapy which also combines a long-term partnership—and we have found that with Ardeo Health and Novagali. I believe Retaine® MGD™ will become the standard of care for those suffering with Meibomian Gland deficiencies."

"Everyone at Ardeo Health is excited to see this newest technology brought to North America. Patients suffering from moderate to severe Dry Eye will now have an alternative to expensive prescription (Rx) therapies," states Robert "Bob" Sykora, RPh, President & CEO of Ardeo Health. "With these partnerships, Ardeo has the best of both worlds—the science of Novagali coupled with the brand recognition and distribution channels of OCuSOFT®."

Jerome Martinez, Chairman of Novagali Pharma, concludes "We are very pleased to be able to announce, today, the signing of this agreement involving two major American ophthalmology players. Given their proven expertise on the North American ophthalmology market, OCuSOFT®'s teams will no doubt make Nova23041's launch in the United States and Canada a success that will enable us to extend the distribution of our unique formulation for treating dry eye symptoms around the world. This agreement confirms the growing reputation of the products and technologies developed by Novagali Pharma in the United States."

About OCuSOFT, Inc.

OCuSOFT, Inc. is a Richmond, TX USA-based ophthalmic research, development and supply company with an established reputation for innovation, particularly in the area of Ocular Surface Disease (OSD). Since 1986, OCuSOFT® has served the ophthalmic industry with a unique selection of proprietary brands including over-the-counter (OTC) and prescription products. A pioneer in ophthalmology, OCuSOFT® introduced the first eyelid cleanser, the first topical anesthetic gel, the first "leave-on" antibacterial eyelid cleaner, the first prescription-only supplement for Dry Eyes and the first supplement to enhance botulinum toxin injections. Today, the company is most recognized for its #1 Doctor Recommended Brand of Eyelid Cleansers, OCuSOFT® Lid Scrub™, in addition to its standing as the preferred distributor of ophthalmic products and supplies by eye care professionals. For more information, please call 800-233-5469 or visit www.ocusoft.com.

About Ardeo Health LLC

Ardeo Health, founded in 2007, is a Suwanee, GA USA-based healthcare company that specializes in research, development, and licensing of advanced technology pharmaceutical products, consumer health products, and medical devices. Ardeo Health is dedicated to the pursuit of products and technologies leading to the effective treatment and cure of ophthalmic and dermatologic diseases. For more information, please contact [email protected] or visit www.ardeohealth.com.

About Novagali Pharma, S.A.

Founded in 2000, Novagali Pharma SA is a pharmaceutical company that develops innovative ophthalmic products for all segments of the eye. Thanks to its three proprietary technology platforms, the Company has an advanced portfolio of highly innovative products, one of which is already on sale and two of which are undergoing phase III clinical trials. In 2009, Frost & Sullivan recognized Novagali with the Award for Industry Innovation & Advancement of the Year, for its proprietary emulsion technology platforms, and Siemens awarded the company the "Health Award" Grand Prix de l'Innovation for Novasorb®. Novagali Pharma carried out a successful IPO in July 2010 enabling the Company to raise euro 22 million. Novagali Pharma is listed on NYSE Euronext Paris - Compartment C. ISIN code: FR0010915553 - Ticker: NOVA.

SOURCE OCuSOFT, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED